[Advantages of salbutamol-tacholiquine inhalation over orciprenaline-tacholiquine inhalation in bronchial asthma].
D000328:Adult; D000336:Aerosols; D000368:Aged; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002082:Butylamines / Q000008:administration & dosage / Q000009:adverse effects; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004983:Ethanolamines / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D006985:Hyperventilation / Q000139:chemically induced; D000860:Hypoxia / Q000139:chemically induced; D008297:Male; D009921:Metaproterenol / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D008875:Middle Aged; D010101:Oxygen Consumption / Q000187:drug effects; D010627:Phenethylamines / Q000008:administration & dosage* / Q000009:adverse effects; D012138:Respiratory Therapy; D013610:Tachycardia / Q000139:chemically induced
D000336:Aerosols; D001993:Bronchodilator Agents; D002082:Butylamines; D004338:Drug Combinations; D004983:Ethanolamines; D010627:Phenethylamines; D009921:Metaproterenol
Vorteile der Salbutamol-Tacholiguin- gegenüber der Orciprenalin-Tacholiguin-Inhalation bie Bronchialasthma.